Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Liver fibrosis is a substantial risk factor for liver cancer development. In this issue, we focus on molecular and cellular mechanisms of hepatic fibrogenesis and discuss therapeutic implications.
In this Review, Murphy and Zaki discuss changes in the incidence and mortality of colorectal cancer, including trends by age and birth cohort, and consider the contributions of early-life exposures and emerging risk factors.
Increasing evidence shows a role of cellular stress responses in nonalcoholic steatohepatitis (NASH) and liver fibrosis pathogenesis. This Review provides a comprehensive overview of the molecular mechanisms involved in cellular stress in fibrogenesis and their role in NASH progression.
Hormones released in the gut orchestrate pivotal physiological processes. In this Review, the authors present an overview of gut hormones that are involved in the regulation of metabolism, and discuss their action in the gastrointestinal system and beyond.
In this Review, Arrese and colleagues discuss the intersection of nonalcoholic fatty liver disease and alcohol-related liver disease, including their pathophysiology, clinical management and suggestions for future research.
Hepatic stellate cells (HSCs) drive liver fibrosis and are closely linked to liver cancer development. This comprehensive Review provides an in-depth analysis of the specific characteristics of HSCs in cancer, highlighting therapeutic implications based on progress in clarifying HSC biology.
Imaging techniques for assessing liver fibrosis are advancing. This Clinical Outlook article discusses the best practices and reviews emerging options for magnetic resonance and ultrasound-based elastography.
In this Review, Huang et al. discuss the current status of hepatocellular carcinoma surveillance, the remaining challenges, including the changing aetiology of liver disease, and strategies to improve the utilization and quality of surveillance.
